CapsoVision (CV) FCF Margin (2024 - 2025)
CapsoVision's (CV) quarterly FCF Margin came in at 196.38% in Q4 2025, down 3997.0% year-on-year from 5.04% in Q4 2024, and down 22.36% quarter-over-quarter from 160.49% in Q3 2025.
CapsoVision (CV) FCF Margin (2024 - 2025) Analysis & Trends
CapsoVision has disclosed FCF Margin across 2 years of filings, most recently posting 196.38% for Q4 2025.
- FCF Margin for Q4 2025 came in at 196.38%, down 3997.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 131.98% (changed N/A YoY), and the FY2025 annual result was 169.35%, up 285.0% from the prior year.
- FCF Margin came in at 196.38% for Q4 2025 at CapsoVision, down from 160.49% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 156.4% in Q4 2024 to a low of 238.03% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 25.51% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | -1.28% |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 3.98% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 6.68% |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 37.67% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 15.44% |
| 10 | CapsoVision | 176.55 Mn | 166.44 Mn | 1.95 Mn | -196.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -196.38% |
| Sep 30, 2025 | -160.49% |
| Dec 31, 2024 | -156.40% |
| Sep 30, 2024 | -238.03% |